Jazz Pharmaceuticals plc (JAZZ) Q4 FY25 Earnings Call

Zanidatamab and rare-oncology growth offset expected sleep-franchise declines in 2026.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-25
Length62 minutes
EPS$5.76
EPS consensus$5.65
Revenue$1.1B
Revenue consensus$1.2B

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All JAZZ earnings ยท Back to JAZZ overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.